These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34419421)

  • 1. Impact of patient face mask use on endophthalmitis after intravitreal anti-VEGF injections.
    Hébert M; You E; Hammamji K; Bourgault S; Caissie M; Tourville É; Dirani A
    Can J Ophthalmol; 2022 Dec; 57(6):364-369. PubMed ID: 34419421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Influence of Universal Face Mask Use on Endophthalmitis Risk after Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    ; Patel SN; Tang PH; Storey PP; Wolfe JD; Fein J; Shah SP; Chen E; Abbey A; Ferrone PJ; Shah CP; Liang MC; Stem MS; Ali Khan M; Yonekawa Y; Garg SJ
    Ophthalmology; 2021 Nov; 128(11):1620-1626. PubMed ID: 34019955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Legal obligation in the general population: face mask influence on endophthalmitis after intravitreal injection.
    Neubauer J; Gklavas K; Kortüm F; Gosheva M; Bartz-Schmidt KU; Ziemssen F
    Graefes Arch Clin Exp Ophthalmol; 2023 Jan; 261(1):97-102. PubMed ID: 35932321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EFFECT OF PHYSICIAN FACE MASK USE ON POSTINJECTION ENDOPHTHALMITIS.
    Fortes BH; Astafurov KV; Hodge DO; Smith WM; Barkmeier AJ; Olsen TW; Iezzi R; Bakri SJ
    Retina; 2022 Nov; 42(11):2120-2127. PubMed ID: 35963006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-intravitreal injection endophthalmitis pattern during the COVID-19 pandemic with implementation of patients' masking.
    Mirghorbani M; Bazvand F; Riazi-Esfahani H; Bahar MM; Yaseri M; Zarei M
    Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3657-3664. PubMed ID: 35678839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in Endophthalmitis Associated With Intravitreal Injection of Anti-VEGF Agentsat a Tertiary Referral Center.
    Reyes-Capo DP; Yannuzzi NA; Smiddy WE; Flynn HW;
    Ophthalmic Surg Lasers Imaging Retina; 2021 Jun; 52(6):319-326. PubMed ID: 34185586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Pandemic Is Not Associated with Endophthalmitis Decrease after Anti-Vascular Endothelial Growth Factor Injections.
    Lum F; Li S; Liu L; Li C; Parke DW; Williams GA
    Ophthalmology; 2022 Jun; 129(6):719-721. PubMed ID: 35041903
    [No Abstract]   [Full Text] [Related]  

  • 10. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
    Bavinger JC; Yu Y; VanderBeek BL
    Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period.
    Pancholy M; Storey PP; Levin HJ; Obeid A; Patel SN; Kuley B; Hsu J; Spirn MJ; Fineman M; Klufas MA; Gupta O; Ho AC; Garg SJ
    Curr Eye Res; 2021 Sep; 46(9):1370-1377. PubMed ID: 33522314
    [No Abstract]   [Full Text] [Related]  

  • 12. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
    Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.
    Gregori NZ; Flynn HW; Schwartz SG; Rosenfeld PJ; Vaziri K; Moshfeghi AA; Fortun JA; Kovach JL; Dubovy SR; Albini TA; Davis JL; Berrocal AM; Smiddy WE
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):643-8. PubMed ID: 26114845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and visual outcomes of acute endophthalmitis post intravitreal injection of anti-vascular endothelial growth factors in a single referral center.
    Gonzalez-Gonzalez LA; Knickelbein JE; Doft BH; Balasubramani GK; Wisniewski S
    Int Ophthalmol; 2023 Mar; 43(3):867-876. PubMed ID: 36103102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Physician Face Mask Use on Endophthalmitis After Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Patel SN; Hsu J; Sivalingam MD; Chiang A; Kaiser RS; Mehta S; Park CH; Regillo CD; Sivalingam A; Vander JF; Ho AC; Garg SJ;
    Am J Ophthalmol; 2021 Feb; 222():194-201. PubMed ID: 32888902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates.
    VanderBeek BL; Bonaffini SG; Ma L
    Ophthalmology; 2015 Nov; 122(11):2311-2315.e1. PubMed ID: 26281823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
    Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Endophthalmitis after Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength.
    Stem MS; Rao P; Lee IJ; Woodward MA; Faia LJ; Wolfe JD; Capone A; Covert D; Dass AB; Drenser KA; Garretson BR; Hassan TS; Margherio A; Oh KT; Raephaelian PV; Randhawa S; Sneed S; Trese MT; Yedavally S; Williams GA; Ruby AJ
    Ophthalmol Retina; 2019 Jan; 3(1):3-7. PubMed ID: 30929813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
    Freiberg FJ; Brynskov T; Munk MR; Sørensen TL; Wolf S; Wirth MA; Becker M; Michels S
    Retina; 2017 Dec; 37(12):2341-2346. PubMed ID: 28099318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTIONS DURING THE COVID-19 PANDEMIC WITH IMPLEMENTATION OF UNIVERSAL MASKING.
    Naguib MM; Ghauri S; Mukhopadhyay A; Schefler AC
    Retina; 2021 Nov; 41(11):2208-2214. PubMed ID: 33958531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.